A5027753564- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Diet, Metabolism, and Disease
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Drug-Induced Hepatotoxicity and Protection
- Endoplasmic Reticulum Stress and Disease
- Hepatitis Viruses Studies and Epidemiology
- Gastrointestinal Bleeding Diagnosis and Treatment
- Lipid metabolism and biosynthesis
- Venous Thromboembolism Diagnosis and Management
- Peroxisome Proliferator-Activated Receptors
- Lipid metabolism and disorders
- Diet and metabolism studies
- Cancer, Lipids, and Metabolism
- Gastroesophageal reflux and treatments
- Gastrointestinal disorders and treatments
- Abdominal vascular conditions and treatments
- Hemophilia Treatment and Research
University of Virginia
2015-2024
Leicester Royal Infirmary
2024
University of Michigan
2010-2024
St. Michael's Hospital
2024
University of Toronto
2024
University of Virginia Medical Center
2010-2023
University of Virginia Health System
2013-2023
Hudson Institute
2021
John Wiley & Sons (United Kingdom)
2021
Istituto Tecnico Industriale Alessandro Volta
2021
This position paper has been approved by the AASLD and represents of association. These recommendations provide a data-supported approach. They are based on following: (1) formal review analysis recently published world literature topic; (2) American College Physicians Manual for Assessing Health Practices Designing Practice Guidelines1; (3) guideline policies, including Policy Development Use Guidelines Gastroenterological Association Statement Guidelines2; (4) experience authors in...
We characterized 70 consecutive patients with cryptogenic cirrhosis to assess major risks for liver disease. Each patient was reevaluated past alcohol exposure, scored by the International Autoimmune Hepatitis (IAH) score and assessed viral hepatitis nonalcoholic steatohepatitis (NASH). The results were compared 50 NASH patients, 39 age over from C, 33 caused primary biliary (PBC). Among group, 49 (70%) female, mean 63 +/- 11 years. Although ascites variceal bleeding common, almost one half...
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for Study Liver Diseases (AASLD) Guidance document was published.1 This new AASLD reflects many advances in field pertinent to any practitioner caring patients and emphasizes noninvasive risk stratification therapeutics. A separate guideline focused on management context diabetes been written jointly by Clinical Endocrinology AASLD.2 Given significant...
Normal coagulation has classically been conceptualized as a Y-shaped pathway, with distinct "intrinsic" and "extrinsic" components initiated by factor XII or VIIa/tissue factor, respectively, converging in "common" pathway at the level of FXa/FVa (prothrombinase) complex. Until recently, lack an established alternative concept hemostasis meant that most physicians view "cascade" model physiology. This reinforced fact screening tests (APTT, prothrombin time--INR) are often used though they...
Inhibition of apoptosis signal-regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis animal models nonalcoholic steatohepatitis. We evaluated the safety efficacy selonsertib, selective inhibitor alone or combination with simtuzumab, patients steatohepatitis stage 2 3 liver fibrosis. In this multicenter phase trial, 72 were randomized receive 24 weeks open-label treatment either 6 18 mg selonsertib orally once daily without once-weekly injections...
Objective: To provide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought standardize management of patients with failure within participating centers. Methods: In areas where consensus could not be reached because divergent practices and paucity studies in patients, additional information was gleaned intensive care literature on intracranial hypertension non-acute patients. Experts diverse fields were included development standard...
Troglitazone is a thiazolidinedione and peroxisome proliferator-activated receptor gamma (PPARgamma) ligand used to treat diabetes mellitus type II. Because hyperinsulinemia may be factor in nonalcoholic steatohepatitis (NASH), we postulated that troglitazone could have beneficial effects this disorder. Our study was initiated before reports of idiosyncratic hepatitis induced by agent completed its recent withdrawal from the market.We studied 10 female patients (age 44 +/- 16) with...
Despite the endogenous coagulopathy of cirrhosis, some patients with cirrhosis experience thrombophilic states. This study aims to determine incidence and predictors venous thromboembolism (VTE), such as deep vein thrombosis (DVT) pulmonary embolism, in hospitalized cirrhosis.A retrospective case-control was performed a tertiary-care teaching hospital over an 8-yr period. A total 113 documented new VTE were compared controls. Risk factors for determined using univariate multivariate...
Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority NAFLD subjects do not have NASH carry significant risk for liver-related adverse outcomes (cirrhosis mortality). Globally, the prevalence approximately 25%. In Asia, gradient high to low rates noted from urban rural areas. Given NAFLD, clinical economic burden can be substantial. With increasing recognition as an important...
Nonalcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis, hepatocellular carcinoma, indications for transplantation. Other than lifestyle modification through diet exercise, there currently no other approved treatments NASH/NAFLD. Although weight loss can be effective, it is difficult to achieve sustain. In contrast, bariatric surgery improve metabolic conditions associated with NAFLD, has...
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers fibrosis 475 patients with NASH bridging (F3) or compensated cirrhosis (F4) enrolled two phase 2b, placebo‐controlled trials simtuzumab. The were terminated after 96 weeks because lack efficacy, so from treatment groups combined. Liver biopsies HVPG measurements (only for F4 fibrosis)...